Drug Database
CA

cannabidiol (Xalex 10)

✓ Approved

RAMM Pharma · CNR1

什么是 cannabidiol?

cannabidiol 是一种治疗药物,由RAMM Pharma研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Xalex 10
公司RAMM Pharma
分子靶点CNR1, TRPV1, GPR55
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

cannabidiol 作用于 3 个分子靶点:

CNR1cannabinoid receptor 1 (CNR, CB1A)
TRPV1transient receptor potential cation channel subfamily V member 1 (VR1)
GPR55G protein-coupled receptor 55 (LPIR1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

cannabidiol 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersEpilepsy✓ Approved

相关研究文献

PubMedJournal of autism and developmental disorders2026-11-18

Limited Efficacy of Cannabidiol on Adaptive Functioning in Boys with Profound Autism.

Oppenheim Hannah H, Umlauf Anya A, Grelotti David D, Grant Igor I et al.

This study examined the effect of cannabidiol (CBD) on adaptive functioning in boys with autism and severe cognitive and behavioral challenges using the Vineland Adaptive Behavior Scales, Third Edition (VABS-3). Primary outcome measures for a randomized, double-blind study of purified CBD and placebo are available online (Trauner et al., 2025). We now present results of a secondary outcome measure of adaptive functioning in a longitudinal design before and after treatment with CBD or placebo. Raw scores were analyzed after noting a floor effect of standard scores. No significant differences in adaptive functioning, except for motor skills, were found between CBD- and placebo-treated participants after 8 weeks of treatment. When compared to its immediate pre-treatment baseline, CBD (but not placebo) was associated with improvement in raw scores for Receptive and Written communication and showed near-significant improvement in Expressive Communication and Personal Skills. When compared to its immediate pre-treatment baseline, placebo was associated with improvement in Community and worsening of Motor Skills raw scores. There was a significant difference in standard and raw scores between CBD and placebo on the Motor Skills domain, with CBD treatment showing superiority to placebo. Although no significant between-group differences were found on most measures of adaptive functioning, within-group changes from zero to 8 weeks of treatment with CBD, but not placebo, showed improved communication skills in severely autistic boys. Future studies should account for placebo effects and severity of symptoms, include a larger sample size and individuals with a range of severity.

PMID 43050040
阅读全文 →
PubMedFrontiers in pharmacology2026-11-18

Effectiveness and safety of different administration routes of medical cannabis or cannabinoids for chronic pain in adults: a systematic review and network meta-analysis with GRADE assessment.

Zhao Min-Hua MH, Jiang Hua-Ling HL, Yu Zi-Jing ZJ, Zhang Chao C et al.

Chronic pain lasting more than 3 months affects more than one billion people globally, ranking as the third most prevalent health burden, after cardiovascular diseases and malignancies. This study aimed to evaluate the effectiveness and safety of medical cannabis or cannabinoids for chronic pain in adults, with prespecified subgroup analyses stratified by pain etiology and administration route to support precision pain management. A systematic literature search was conducted across PubMed, EMBASE, and the Cochrane Library from each database's inception to 15 March 2025. The certainty of evidence was assessed with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. The focused outcomes were pain relief, sleep quality, physical and emotional functioning, anxiety, depression, and adverse events. Twenty-eight studies were involved. Compared to placebo, palmitoylethanolamide (PEA) (SMD = -0.82, 95% CI:-1.36 to -0.29; very low) and tetrahydrocannabinol (THC) (SMD = -0.41, 95% CI:-0.74 to -0.07; low) provided pain relief, and a THC/cannabidiol (CBD) combination significantly improved sleep quality (SMD = -0.43, 95% CI:-0.62 to -0.24; moderate). Regarding safety outcomes, compared to placebo, THC (RR = 3.55, 95% CI: 2.21 to 5.68; low) and THC/CBD (RR = 2.70, 95% CI: 1.60 to 4.53; high) had a relatively high rate of dizziness, and THC (RR = 2.72, 95% CI: 1.76 to 4.22; low) and THC/CBD (RR = 2.92, 95% CI: 1.74 to 4.90; high) had a significant risk of somnolence. THC/CBD elevated nausea risk (RR = 1.81, 95% CI: 1.26 to 2.60; high), while THC increased dry mouth incidence (RR = 3.14, 95% CI: 1.75 to 5.63; moderate). Additionally, compared with placebo for pain relief, CBD demonstrated the greatest effectiveness for cancer-related pain (SMD = -1.62, 95% CI:-2.03 to -1.21), whereas PEA showed optimal effectiveness in non-cancer-related pain (SMD = -0.82, 95% CI:-1.31 to -0.33). This study suggested that medical cannabis or cannabinoids might have certain efficacy for adult chronic pain. PEA and THC provided pain relief, while the THC/CBD combination showed a potential benefit for sleep quality improvement. THC was associated with increased risks of dizziness, somnolence, and dry mouth, and THC/CBD was associated with dizziness, somnolence, and nausea. Subgroup analyses suggested that treatment response might vary by pain etiology and administration route. Given that the evidence certainty is mainly low to very low, the research conclusion still requires a large sample and high-quality randomized controlled trials (RCTs) to be verified. https://osf.io/h56g9, Unique Identifier: 10.17605/OSF.IO/H56G9.

PMID 43047344
阅读全文 →
PubMedNatural product research2026-11-17

Quantitative NMR-based profiling and chemometric analysis of phytocannabinoids in Moroccan Cannabis sativa extracts (beldia variety).

Héritier Uwikunda Serondo S, Metouekel Amira A, Hamdoun Ghanem G, El Amri Hamid H et al.

Cannabis sativa L. has been used for both economic and medical purposes, due to its numerous bioactive compounds called phytocannabinoids and non-cannabinoids, such as the psychoactive Δ9-tetrahydocannabinol (Δ9-THC) as well as the non-psychoactive cannabidiol (CBD). With the legalisation of cannabis in Morocco in 2021, there is a pressing need for reliable and efficient methods to quantify cannabinoid content in local cultivars. This work proposes the use of the 1D CPMG NMR technique combined with multivariate statistical analysis to identify and quantify five major cannabinoids in 17 extracts collected from different sites in northern Morocco. The results obtained revealed the predominance of THC (average = 7.84 mmol·L-1) and CBD (average = 0.98 mmol·L-1) which is consistent with known cannabinoid biosynthetic pathways of phytocannabinoids. The developed method enables accurate measurement of cannabinoid levels in various samples, making it valuable for the cannabis industry.

PMID 43043372
阅读全文 →
PubMedEpileptic disorders : international epilepsy journal with videotape2026-11-17

Real-world safety profiles of newer antiseizure medications: A pharmacovigilance study based on FDA Adverse Event Reporting System database.

He Zimeng Z, Li Tongyue T, Chang Yuyan Y, Liu Yang Y et al.

This study aimed to systematically evaluate and compare the post-marketing safety of four newer antiseizure medications (ASMs)-brivaracetam (BRV), cannabidiol (CBD), cenobamate (CNB), and fenfluramine (FFA). A pharmacovigilance study was conducted using data from the FAERS database (Q1 2016-Q4 2024). Disproportionality analyses were performed to detect adverse event (AE) signals using three algorithms. Subgroup analyses were stratified by age, sex, reporter, and treatment strategy. We employed multivariable logistic regression, adjusted for covariates including age, sex, weight, dose, and concomitant medications, to validate associations between ASMs and specific AEs and to identify potential influencing factors. Bayesian network analysis was conducted to explore conditional dependencies among variables. Hospitalization risk was evaluated based on system organ classes. After data cleaning, 13 763 reports were included. We identified 308 positive preferred term (PT) signals. Seizure-related AEs were frequently reported. All four ASMs had the PT of seizure cluster, with each exhibiting distinct AE profiles: BRV with psychiatric disorders, CBD with gastrointestinal events, CNB with visual dysfunction, and FFA with valvular heart disease (VHD). Children had higher reporting odds of seizure with BRV and CBD, while reporting odds of FFA-related VHD were lower in children; polytherapy was associated with higher reporting odds of somnolence, and AE reporting patterns varied by reporter source. Both CBD-related gastrointestinal events and FFA-related cardiac events exhibited dose-dependent effects. Infection-related AEs were associated with higher odds of hospitalization for multiple ASMs. This study comprehensively characterizes the safety profiles of newer ASMs and highlights the importance of tailored AE monitoring based on specific ASM and patient characteristics.

PMID 43042732
阅读全文 →
PubMedJournal of affective disorders reports2026-11-17

Effectiveness and Safety of Cannabis on Anxiety Treatment Outcomes: A Systematic Review.

Kotecha Pareeta P, Perez-Vilar Silvia S, Lloyd Joshua J, Sandhu Sukhminder K SK et al.

We assessed controlled non-interventional studies and randomized clinical trials (RCTs) evaluating THC-containing cannabis' safety and effectiveness for anxiety. We searched PubMed, Embase, APA PsychInfo, and Cochrane databases in February 2023 for clinical studies that reported patient-level controlled quantitative assessments of anxiety outcomes following cannabis treatment. Exclusion criteria included: publication before 2000, in non-English language, assessment of topical treatment or containing <0.3% tetrahydrocannabinol, and FDA-approved products. We assessed risk of bias via RoB2/ROBINS-I, and rated evidence quality using the GRADE approach. PROSPERO:CRD42023411999. From 6,453 search records, 4 RCTs and 1 observational study met inclusion criteria. All studies involved patients with severe comorbid medical conditions, with anxiety assessed as a secondary outcome, limiting generalizability to primary anxiety disorders. Interventions included THC-rich cannabis oil for fibromyalgia, cannabinoids for obsessive-compulsive disorder (OCD), cannabidiol (CBD)-enriched extracts for Parkinson's disease, nabiximols (THC:CBD 1:1) for multiple sclerosis (MS), and cannabis for chronic non-cancer pain. Anxiety was measured via self-reported scales. Due to heterogeneity in anxiety measures, results were synthesized narratively. Compared with placebo, the OCD RCT showed significant anxiety worsening [4.31 (1.70, 6.92)]; the Parkinson's disease RCT non-significant improvement [-0.82 (-1.97, 0.33)], and the fibromyalgia and MS RCTs show no significant effects [0.38 (-2.91, 3.67); -2.00 (-7.51, 3.51)]. The pain observational study reported no initial significant effect on anxiety -0.30 (-1.53, 0.93). Quality of life (QoL) worsened with THC in Parkinson's [-0.14 (-0.23, -0.04)] and showed non-significant improvement in MS [0.35 (-1.09, 1.79)]. The evidence quality was rated low to moderate. Evidence on THC-containing cannabis' effects on anxiety is limited and inconsistent, with heterogeneous measures and mixed findings preventing meaningful quantitative synthesis. Across studies, no consistent evidence of benefit was observed. Higher-quality studies with standardized outcomes are needed to clarify their impact on anxiety and quality of life. Evidence quality was rated as low to moderate, driven by small sample sizes, short durations, and limited generalizability.

PMID 43041801
阅读全文 →
PubMedJAMA pediatrics2026-11-16

Cannabidiol for Disruptive Behavior-The Verdict Is In.

Aran Adi A, Cayam-Rand Dalit D

PMID 43037968
阅读全文 →

注册免费账户还可查看另外 8122 篇文献

免费注册查看全部文献 →

了解更多cannabidiol